Pacer Advisors
VKTX icon

Pacer Advisors’s Viking Therapeutics VKTX Stock Holding History

Pacer Advisors’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$65K Buy
+1,661
New +$53.7K ﹤0.01% 1977
2024
Q3 		– Sell
-1,909
Closed -$101K – 2708
2024
Q2 		$101K Buy
1,909
+1,317
+222% +$86.3K ﹤0.01% 2336
2024
Q1 		$48.5K Buy
+592
New +$26.3K ﹤0.01% 3177
2021
Q2 		– Sell
-8,140
Closed -$51K – 1563
2021
Q1 		$51K Sell
8,140
-232
-3% -$1.63K ﹤0.01% 1435
2020
Q4 		$47K Buy
8,372
+2,597
+45% +$15.7K ﹤0.01% 1421
2020
Q3 		$34K Buy
+5,775
New +$39.8K ﹤0.01% 1324
2018
Q4 		– Sell
-18,994
Closed -$331K – 1028
2018
Q3 		$331K Buy
+18,994
New +$226K 0.01% 937

Other funds holding VKTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Pacer Advisors's VKTX Position: Q2 2026 in Review

Pacer Advisors opened a new position in Viking Therapeutics (VKTX) in Q2 2026: 1,661 shares worth $65K. The stake represents ﹤0.01% of the portfolio and ranks #1977 among its holdings. This is a return to the name: Pacer Advisors previously reported a position in VKTX as recently as Q2 2024.

Pacer Advisors first reported a position in VKTX in Q3 2018 and has held it in 7 quarters since. The position peaked at $331K in Q3 2018. 436 funds tracked by Wall St. Rank hold VKTX as of Q2 2026.

  • Pacer Advisors held 1,661 shares of Viking Therapeutics worth $65K as of Q2 2026.
  • Viking Therapeutics was a new Pacer Advisors position in Q2 2026.
  • Viking Therapeutics made up ﹤0.01% of Pacer Advisors's portfolio in Q2 2026, its #1977 holding.
  • Pacer Advisors first reported a position in Viking Therapeutics in Q3 2018 and has held it in 7 quarters since.
  • Pacer Advisors's Viking Therapeutics position peaked at $331K in Q3 2018.
  • 436 funds tracked by Wall St. Rank held Viking Therapeutics as of Q2 2026.

Based on Pacer Advisors's 13F filing for Q2 2026, filed 13 Aug 2026.